Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
Forget 'Outer Banks.' These Gen Z-ers just want to watch 'M*A*S*H*' and 'Gilmore Girls.' - 2Three arrested in Paris after attempted bomb attack outside Bank of America
- 3Death toll from floods in Afghanistan rises to 61
- 4Audits of 6 Specialty Mixed drinks
- 5HR exec caught on Coldplay 'kiss cam' with boss finally breaks her silence: 'I made a bad decision and had a couple of High Noons'
- Instructions to Help a Friend or family member Determined to have Cellular breakdown in the lungs
- As Western heat wave ends, scientists try to make sense of its length and intensity
- Posts falsely claim Netanyahu video fabricated to cover up his death
- Zendaya serves bridal-coded fashion with old, new and borrowed gowns for ‘The Drama’ press tour
- Europe could get 42 more days of summer by the year 2100 due to climate change
- Poll: 62% of Americans would oppose U.S. military action in Greenland
- Experience Sports in Dubai: A Daredevil's Aide
- Tire Brands for Senior Drivers: Guaranteeing Security and Solace
- Journeys That could only be described as epic: Delightful Voyage Lines All over the Planet
